U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09026353
Filing Date		1998-02-19
First Named Inventor ARG		ENTA, ET AL.
Art Unit		3735
Examiner Name	LACY	rk, J.
Attorney Docket Number		0101-P00636US3

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue C	ate	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where les or Relev	
	1										
If you wisl	h to a	d additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number Kind Publication Name of Patentee or Applicant Re		Releva		Lines where les or Relev					
	1										
If you wish	h to a	dd additional U.S. Publi						d button	$\overline{}$		
				FOREIG	3N PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	where Rele	or Relevant	T5
	1										
If you wisl	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		_
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Ţ5				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		09026353
	Filing Date		1998-02-19
	First Named Inventor ARGE Art Unit Examiner Name LACY		ENTA, ET AL.
			3735
			YK, J.
	Attorney Docket Number		0101-P00636US3

1	RCI v. BlueSky. BlueSky Medical Group Inc. and Richard Weston's motion to exclude certain expert testimony dated April 21, 2006.	
2	KCI v. BlueSky: Medela's Molion to exclude proposed trial testmony of plaintiff's experts Louis C. Argenta, Dennis P. Orgill and Wilson C. Hayes, dated April 21, 2006.	
3	KCl v. BlueSky. Plantiff's motion to exclude opinions of Vincent Pizzooni dated April 21, 2006	
4	KCI v. BlueSky; Plantiff's motion to exclude certain opinions of Michael O'Neil dated April 21, 2006,	
5	KCI v. BlueSky. Medela's response to plantiff's motion to exclude opinions of Harret Hopf with Exhibits dated April 28, 2006.	
6	KCI v. BlueSky: Medela's response to plaintiff's motion to exclude opinions of Michael O'Nell and motion to exclude opinions of John T. Gookasian with Exhibits dated April 28, 2006	
7	KCI v. BlueSky: Medela's response to plantiff's motion to exclude opinions of James Spatin dated April 28,2006.	
8	KCI v. BlueSky. Plantiff's response to Medela's motion to exclude proposed trial testimony of Louis C. Argenta, Dennis P. Orgill, and Wilson C. Hayes, dated May 1, 2006.	
9	KCI v. BlueSky. Medela's Renewed Motion for Judgment as a Matter of Law, or, in the alternative, a New Trial, on Patent Invalidity, dated September 13, 2006.	
10	KCI v. BlueSky; Medela's Motion for a New Trial on Unenforceability, dated September 13, 2006.	
11	Claim Chart of Asserted Claims of U.S. Patent 5,636,643 to Argenta, 3 pages	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09026353
iling Date		1998-02-19
First Named Inventor ARG		ENTA, ET AL.
Art Unit		3735
Examiner Name LACY		rk, J.
Attorney Docket Number	er	0101-P00636US3

Examine			Date Considered reference considered, whether or not citation is in conformance with MPEP 609		
			EXAMINER SIGNATURE		
If you wis	h to a	dd add	ditional non-patent literature document citation information please click the Add b	outton Add	_
	16				
	15	KCI	v, BlueSky, Second Amended Order Construing Patent '643 and '081 Claim Terms dated	June 29, 2006	
	14		v. BlueSky, Letter from Valery Gillevich, M.D. to Kirt S. O'Neill, dated May 28, 2006 concellation of Russian article.	ming review of English	
	13		v. BlueSky: Letter dated December 9, 2005 from the Honorable Royal Ferguson to attorn dring claim construction.	neys in KCl v. BlueSky	
	12	Clain	n Invalidity Analysis of U.S. Patent 5,636,643 to Argenta, et al., 34 pages, March 2004,		

1 See Kin Codes of USPTO Patent Documents at year LISPTO, COD or MRCP 801.84. ² Enter office that issued the document, by the how-later code (WIPO Standard ST3.) ³ for Juapence patent councersts, it has indicated on the year of the Emproving test percent percent any temperature of the Control and process the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ³ Applicant is to place a check mark here if English language translations in attacked.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number Filing Date First Named Inventor ARG		09026353
			1998-02-19
			ENTA, ET AL.
	Art Unit		3735
Examiner Name LACY Attorney Docket Number		LACY	rk, J.
		er	0101-P00636US3

48 488

CERTIFICATION STATEMENT

Please see 37	CFR 1	.97 and	1.98 to make the	appropriate	selection(s)	
---------------	-------	---------	------------------	-------------	------------	----	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(c).

See attached certification statement.

Niels Haun

- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- __ IZ⊓ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

norm or the signature.			
Signature	/Niels Haun/	Date (YYYY-MM-DD)	2006-10-04

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. U.S. operatment of Commence, P.O. Box 1450, Alexandria, V.S. 231-1450, DNOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan Koffice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested in the contraction of the contraction of the patient o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such Adeckouse shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record vals filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to public insepections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.